|
US7611713B2
(en)
|
1993-03-05 |
2009-11-03 |
Pharmexa Inc. |
Inducing cellular immune responses to hepatitis B virus using peptide compositions
|
|
US20040096445A1
(en)
*
|
1999-06-30 |
2004-05-20 |
John Sidney |
Subunit vaccines with A2 supermotifs
|
|
US9266930B1
(en)
|
1993-03-05 |
2016-02-23 |
Epimmune Inc. |
Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
|
|
CA2377525A1
(en)
*
|
1999-07-19 |
2001-03-29 |
Epimmune, Inc. |
Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
|
|
EP1230268B1
(en)
|
1999-11-18 |
2009-10-14 |
Pharmexa Inc. |
Heteroclitic analogs of class i epitopes
|
|
US7026443B1
(en)
|
1999-12-10 |
2006-04-11 |
Epimmune Inc. |
Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
|
|
WO2001041787A1
(en)
*
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
|
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
|
WO2001074847A2
(en)
*
|
2000-03-30 |
2001-10-11 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
|
|
CA2407104A1
(en)
*
|
2000-05-12 |
2001-11-22 |
Northwest Biotherapeutics, Inc. |
Method to increase class i presentation of exogenous antigens by human dendritic cells
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
CA2464239C
(en)
|
2001-10-23 |
2016-07-12 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
GB0203420D0
(en)
|
2002-02-13 |
2002-04-03 |
Oxford Biomedica Ltd |
Peptide
|
|
GB0203419D0
(en)
|
2002-02-13 |
2002-04-03 |
Oxford Biomedica Ltd |
Peptide
|
|
PL1620456T3
(pl)
*
|
2003-04-18 |
2014-06-30 |
Ose Pharma Int Sa |
Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
|
|
TWI262192B
(en)
*
|
2003-07-01 |
2006-09-21 |
Univ Nat Taiwan |
Labeling peptide for nasopharyngeal carcinoma (NPC) cells
|
|
GB0716992D0
(en)
|
2007-08-31 |
2007-10-10 |
Immune Targeting Systems Its L |
Influenza antigen delivery vectors and constructs
|
|
GB0408164D0
(en)
|
2004-04-13 |
2004-05-19 |
Immune Targeting Systems Ltd |
Antigen delivery vectors and constructs
|
|
JP2007277092A
(ja)
*
|
2004-06-17 |
2007-10-25 |
Univ Kurume |
前立腺関連抗原由来ｈｌａ−ａ２結合性ペプチド
|
|
EP1840133A1
(en)
*
|
2006-03-29 |
2007-10-03 |
Global Biotech Development Corp. Ltd. |
New immunomodulating oligopeptides
|
|
US9511134B2
(en)
|
2006-05-18 |
2016-12-06 |
Epimmune Inc. |
Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
|
|
US8282938B2
(en)
|
2008-11-28 |
2012-10-09 |
National Institute Of Infectious Diseases |
Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
|
|
WO2010086294A2
(en)
|
2009-01-28 |
2010-08-05 |
Epimmune Inc. |
Pan-dr binding polypeptides and uses thereof
|
|
CA3197245A1
(en)
*
|
2010-05-14 |
2011-11-17 |
The General Hospital Corporation |
Compositions and methods of identifying tumor specific neoantigens
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
EP3082853A2
(en)
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
WO2015130488A2
(en)
|
2014-02-28 |
2015-09-03 |
Immunotope, Inc. |
Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
|
IL302102A
(en)
|
2015-05-20 |
2023-06-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
CN117801069A
(zh)
|
2016-10-07 |
2024-04-02 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
|
WO2018065628A2
(en)
|
2016-10-07 |
2018-04-12 |
Enterome |
Microbiota sequence variants of tumor-related antigenic epitopes
|
|
CN110022893B
(zh)
*
|
2016-10-07 |
2023-12-29 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
|
WO2018126060A1
(en)
|
2016-12-28 |
2018-07-05 |
Invvax, Inc. |
Influenza vaccines
|
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
CN111093691A
(zh)
|
2017-04-03 |
2020-05-01 |
内恩疗法公司 |
蛋白质抗原及其用途
|
|
NL2019814B1
(en)
*
|
2017-10-26 |
2019-05-06 |
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis |
Methods for producing a MHC multimer.
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
FI3773689T3
(fi)
|
2018-04-11 |
2023-01-31 |
|
Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
|
|
US12246067B2
(en)
|
2018-06-19 |
2025-03-11 |
Biontech Us Inc. |
Neoantigens and uses thereof
|